-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly: The overall safety profile for patients treated with pirobrutinib in the BRUIN CLL-313 trial was similar to the previously reported trial.

智通財經·12/09/2025 12:33:08
語音播報
Eli Lilly: The overall safety profile for patients treated with pirobrutinib in the BRUIN CLL-313 trial was similar to the previously reported trial.